ABG
APTO

Ally Bridge Group’s Aptose Biosciences, Inc. APTO Stock Holding History

Ally Bridge Group’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,131
Closed -$8.42M – 39
2021
Q1 		$8.42M Hold
3,131
– – 1.61% 20
2020
Q4 		$6.17M Buy
+3,131
New +$7.36M 1.06% 24

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Ally Bridge Group's APTO Position: Q2 2021 in Review

Ally Bridge Group sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 3,131 shares — an estimated $8.42M sold.

Ally Bridge Group first reported a position in APTO in Q4 2020 and held it in 2 quarters. The position peaked at $8.42M in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Ally Bridge Group reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Ally Bridge Group sold 3,131 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $8.42M.
  • Ally Bridge Group first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 2 quarters.
  • Ally Bridge Group's Aptose Biosciences, Inc. position peaked at $8.42M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.